Gianluca Tomasello1, Fausto Petrelli2, Michele Ghidini1, Alessandro Russo3, Rodolfo Passalacqua1, Sandro Barni2. 1. Oncology Unit, Oncology Department, Azienda Socio Sanitaria Territoriale Ospedale di Cremona, Cremona, Italy. 2. Oncology Unit, Oncology Department, Azienda Socio Sanitaria Territoriale di Bergamo Ovest, Treviglio (Bergamo), Italy. 3. Surgical Oncology Unit, Surgical Department, Azienda Socio Sanitaria Territoriale di Bergamo Ovest, Treviglio (Bergamo), Italy.
Abstract
IMPORTANCE: The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer. However, resection rates of metastases and overall survival with this schedule have never been systematically evaluated in published studies including, but not limited to, the TRIBE (TRIplet plus BEvacizumab) trial. OBJECTIVE: To assess the clinical efficacy of FOLFOXIRI-Bev, including outcomes and rates of surgical conversions. DATA SOURCES: A systematic review was conducted in October 2016 in concordance with the PRISMA guidelines of PubMed, the Cochrane Central Register of Controlled Trials, SCOPUS, Web of Science, Google Scholar, CINAHL, Ovid, and EMBASE using the terms FOLFOXIRI and bevacizumab and (colorectal cancer). STUDY SELECTION: Clinical trials, retrospective case series, and prospective case series that used FOLFOXIRI-Bev for the treatment of initially unresectable metastatic colorectal cancer in humans were included. Individual case reports and retrospective case series with fewer than 10 patients were excluded. DATA EXTRACTION AND SYNTHESIS: Data were extracted independently by 2 reviewers on a predesigned, standardized form. Ultimately, data were aggregated to obtain the pooled effect size of efficacy, according to the random-effects model and weighted for the number of patients included in each trial. MAIN OUTCOMES AND MEASURES: Median overall survival and progression-free survival, overall response rates, and rates of R0 surgical conversions and overall surgical conversions. RESULTS: Eleven FOLFOXIRI-Bev studies published between 2010 and 2016 met the inclusion criteria and were pooled for analysis. The studies included 889 patients, with 877 patients clinically evaluable for overall response rates. The objective response rate to FOLFOXIRI-Bev was 69% (95% CI, 65%-72%; I2 = 25%). The rate of overall surgical conversions was 39.1% (95% CI, 26.9%-52.8%), and the rate of R0 surgical conversions was 28.1% (95% CI, 18.1%-40.8%). Median pooled overall survival was 30.2 months (95% CI, 26.5-33.7 months) in 6 trials with data available, and progression-free survival was 12.4 months (95% CI, 10.0-14.3 months) in 9 trials with data available. In meta-regression analysis, variables significantly associated with conversion surgery were disease limited to the liver and a higher median number of cycles (close to 12). CONCLUSIONS AND RELEVANCE: For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection.
IMPORTANCE: The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer. However, resection rates of metastases and overall survival with this schedule have never been systematically evaluated in published studies including, but not limited to, the TRIBE (TRIplet plus BEvacizumab) trial. OBJECTIVE: To assess the clinical efficacy of FOLFOXIRI-Bev, including outcomes and rates of surgical conversions. DATA SOURCES: A systematic review was conducted in October 2016 in concordance with the PRISMA guidelines of PubMed, the Cochrane Central Register of Controlled Trials, SCOPUS, Web of Science, Google Scholar, CINAHL, Ovid, and EMBASE using the terms FOLFOXIRI and bevacizumab and (colorectal cancer). STUDY SELECTION: Clinical trials, retrospective case series, and prospective case series that used FOLFOXIRI-Bev for the treatment of initially unresectable metastatic colorectal cancer in humans were included. Individual case reports and retrospective case series with fewer than 10 patients were excluded. DATA EXTRACTION AND SYNTHESIS: Data were extracted independently by 2 reviewers on a predesigned, standardized form. Ultimately, data were aggregated to obtain the pooled effect size of efficacy, according to the random-effects model and weighted for the number of patients included in each trial. MAIN OUTCOMES AND MEASURES: Median overall survival and progression-free survival, overall response rates, and rates of R0 surgical conversions and overall surgical conversions. RESULTS: Eleven FOLFOXIRI-Bev studies published between 2010 and 2016 met the inclusion criteria and were pooled for analysis. The studies included 889 patients, with 877 patients clinically evaluable for overall response rates. The objective response rate to FOLFOXIRI-Bev was 69% (95% CI, 65%-72%; I2 = 25%). The rate of overall surgical conversions was 39.1% (95% CI, 26.9%-52.8%), and the rate of R0 surgical conversions was 28.1% (95% CI, 18.1%-40.8%). Median pooled overall survival was 30.2 months (95% CI, 26.5-33.7 months) in 6 trials with data available, and progression-free survival was 12.4 months (95% CI, 10.0-14.3 months) in 9 trials with data available. In meta-regression analysis, variables significantly associated with conversion surgery were disease limited to the liver and a higher median number of cycles (close to 12). CONCLUSIONS AND RELEVANCE: For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection.
Authors: C Cremolini; F Loupakis; C Antoniotti; S Lonardi; G Masi; L Salvatore; E Cortesi; G Tomasello; R Spadi; A Zaniboni; G Tonini; C Barone; S Vitello; R Longarini; A Bonetti; M D'Amico; S Di Donato; C Granetto; L Boni; A Falcone Journal: Ann Oncol Date: 2015-02-23 Impact factor: 32.976
Authors: Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne Journal: Lancet Oncol Date: 2009-11-26 Impact factor: 41.316
Authors: T Gruenberger; J Bridgewater; I Chau; P García Alfonso; M Rivoire; S Mudan; S Lasserre; F Hermann; D Waterkamp; R Adam Journal: Ann Oncol Date: 2014-12-23 Impact factor: 32.976
Authors: D P Modest; I Ricard; V Heinemann; S Hegewisch-Becker; W Schmiegel; R Porschen; S Stintzing; U Graeven; D Arnold; L F von Weikersthal; C Giessen-Jung; A Stahler; H J Schmoll; A Jung; T Kirchner; A Tannapfel; A Reinacher-Schick Journal: Ann Oncol Date: 2016-06-29 Impact factor: 32.976
Authors: Zipeng Lu; Maximilian Weniger; Kuirong Jiang; Stefan Boeck; Kai Zhang; Alexander Bazhin; Yi Miao; Jens Werner; Jan G D'Haese Journal: Target Oncol Date: 2018-08 Impact factor: 4.493
Authors: Maike Zimmermann; Tao Li; Thomas J Semrad; Chun-Yi Wu; Aiming Yu; George Cimino; Michael Malfatti; Kurt Haack; Kenneth W Turteltaub; Chong-Xian Pan; May Cho; Edward J Kim; Paul T Henderson Journal: Mol Cancer Ther Date: 2020-02-06 Impact factor: 6.261
Authors: Linda M Pak; Nancy E Kemeny; Marinela Capanu; Joanne F Chou; Taryn Boucher; Andrea Cercek; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica Journal: J Surg Oncol Date: 2017-11-22 Impact factor: 3.454
Authors: Herbert I Hurwitz; Benjamin R Tan; James A Reeves; Henry Xiong; Brad Somer; Heinz-Josef Lenz; Howard S Hochster; Frank Scappaticci; John F Palma; Richard Price; John J Lee; Alan Nicholas; Nicolas Sommer; Johanna Bendell Journal: Oncologist Date: 2018-12-14